Regulus Therapeutics Inc. (RGLS): Neutral PT Set

RGLS – BMO Capital sets PT at $1. Stock price at the time of this analyst call was $1.25.

Update: As of Dec. 14, 2018, this bearish analyst call has returned -90.53%.

Key Facts Surrounding This News Item

  • RGLS had a POWR Rating of D (Sell) coming into today.
  • RGLS was 6.84% above its 10-Day Moving Average coming into today.
  • RGLS was 5.84% above its 20-Day Moving Average coming into today.
  • RGLS was 4.42% above its 50-Day Moving Average coming into today.
  • RGLS was 13.36% above its 100-Day Moving Average coming into today.
  • RGLS was 12.46% above its 200-Day Moving Average coming into today.
  • RGLS had returned +20.19% year-to-date leading up to today’s news, versus a +2.22% return from the benchmark S&P 500 during the same period.

More Info About Regulus Therapeutics Inc. (RGLS)

Regulus Therapeutics is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. The company was founded in 2007 and is based in San Diego, California. View our full RGLS ticker page with ratings, news, and more.

RGLS at a Glance

RGLS Current POWR Rating™
Overall POWR Rating™
RGLS Current Price $1.42 0.00%
More RGLS Ratings, Data, and News

RGLS Price Reaction

The day of this event (Mar. 8, 2018)
RGLS Closing Price$10.14 32.40%
RGLS Volume469,375
612.47% from avg
Leading up to this event
RGLS 1-mo return10.62%
After this event
RGLS 1-day return31.58%
RGLS 3-day return41.56%
RGLS 5-day return49.70%

RGLS Price Chart

The Top Stocks For 2019

More Regulus Therapeutics Inc. (RGLS) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All RGLS News
Page generated in 0.8845 seconds.